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Abstract
Introduction and hypothesis Mirabegron is a potent and
selective β3-adrenoceptor agonist that may represent an
alternative treatment option in place of antimuscarinics for
patients with overactive bladder.
Methods Patients completed a single-blinded, 2-week pla-
cebo run-in period followed by 12 weeks of randomized
(n=928) double-blinded treatment with mirabegron oral
controlled absorption system (OCAS) 25, 50, 100, or
200 mg once-daily (QD), placebo or tolterodine extended
release (ER) 4 mg QD. The primary endpoint was
change from baseline to end-of-treatment in mean num-
ber of micturition episodes/24 h. Secondary endpoints
included changes in mean volume voided per micturition;
mean number of urinary incontinence, urgency urinary
incontinence, and urgency episodes/24 h; severity of ur-
gency; nocturia; and quality of life measures. Safety
parameters included vital signs, adverse events, laboratory
tests, electrocardiogram measurements and post-void re-
sidual volume.
Results Mirabegron 25, 50, 100, and 200 mg resulted in dose-
dependent reductions (improvements) from baseline to end-of-
treatment in micturition frequency of 1.9, 2.1, 2.1, and 2.2
micturitions/24 h respectively, versus 1.4 micturitions/24 h with
placebo (p≤0.05 for the mirabegron 50-, 100-, and 200-mg
comparisons). There was a statistically significant improvement
with mirabegron compared with placebo for most secondary
endpoints including quality of life variables. While there was a
significant (p<0.05) increase from baseline in pulse rate in the
mirabegron 100-mg and 200-mg groups, this was not associated
with an increased incidence of cardiovascular adverse events.
Conclusions The favorable efficacy and tolerability of mirabe-
gron in this phase II dose-finding study has led to its successful
advancement into a phase III clinical development program.
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Introduction
Overactive bladder (OAB), estimated to occur in >50 mil-
lion people worldwide [1], is characterized by symptoms of
urinary urgency, frequency and nocturia, with/without urgen-
cy incontinence in the absence of lower urinary tract infection
[2]. Antimuscarinic agents are used as first-line pharmacother-
apy in the management of OAB; however, patients often
discontinue antimuscarinics owing to side effects such as dry
mouth, constipation and blurred vision [3], and because of an
often insufficient response to treatment [4, 5].
The β-adrenoceptor is classified into β1, β2 and β3
subtypes. The largely post-synaptic β1-receptors are located
primarily in the heart, but also in the salivary glands, plate-
lets, and the gastrointestinal tract. β2-rceptors are also main-
ly post-synaptic and can be found in blood vessels, bronchi,
skeletal muscle, liver and mast cells, as well as the gastro-
intestinal tract. The β3 subtype was first identified in adi-
pose tissue, but has also been identified in bladder smooth
muscle tissue (detrusor muscle). In the human bladder, the
β3 subtype promotes detrusor relaxation and urine storage
[6–8]. β3-adrenoceptor mRNA is predominantly expressed
in the human urinary bladder, with 97 % of total β-
adrenoceptor mRNA expressed by the β3 subtype and only
1.5 % and 1.4 % expressed by the β1 and β2 subtypes
respectively [9]. Whereas antimuscarinic agents bind to
muscarinic receptors in the bladder and inhibit involuntary
bladder contractions, stimulation of the β3 receptors in the
detrusor muscle of the bladder elicits relaxation of the
bladder muscle during the storage phase of the micturition
cycle [6–8]. Hence β3-adrenoceptor agonists improve the
storage capacity of the bladder without inhibiting bladder
voiding. These observations suggest that drugs which act at
β3-adrenoceptors may have therapeutic potential in the
treatment of the symptoms of OAB [9, 10].
Mirabegron is a β3-adrenoceptor agonist whose clinical
efficacy was first evaluated in a phase II proof-of-concept
study in which patients were randomized to receive mirabe-
gron 100 mg or 150 mg twice-daily (BID), placebo, or
tolterodine extended release (ER) 4 mg once-daily (QD)
for 4 weeks. As no difference in efficacy was seen between
the 100-mg and 150-mg BID doses, it was deduced that the
maximum therapeutic dose of mirabegron was a total daily
dose of 200 mg. The results of a subsequent phase II,
randomized, double-blinded, placebo- and active-controlled
clinical study (Clinicaltrials.gov number: NCT00337090)
evaluating the efficacy and dose–response relationship of
mirabegron utilizing a QD oral controlled absorption system
(OCAS) formulation in patients with OAB are presented
here. OCAS is a hydrophilic gel-forming matrix tablet that
allows more steady absorption of mirabegron than seen with
the original, immediate-release formulations, which were
associated with high peak-to-trough fluctuations in plasma
concentration and a considerable food effect. Tolterodine
extended release (ER) is an antimuscarinic agent commonly
used to treat the symptoms of OAB; it was included (at a
daily dose of 4 mg) as the active control in order to validate
the study and to enable the efficacy and safety of mirabe-
gron to be placed in context against a commonly used
therapy (although the study was not powered for a head-
to-head comparison).
Materials and methods
Study patients
Enrolled patients were men and women ≥18 years of age
experiencing symptoms of OAB for ≥3 months with frequency
of micturition on average ≥8 times per 24 h and at least three
episodes of urgency (grade 3 or 4) [11], with or without incon-
tinence, during a 3-day micturition diary period at baseline.
Major exclusion criteria at study entry included clinically
significant bladder outflow obstruction; significant post-void
residual (PVR) volume (>200 ml); incontinence where stress
was the predominant factor; indwelling catheters or intermit-
tent self-catheterization; diabetic neuropathy; symptomatic
urinary tract infection, interstitial cystitis, bladder stones, pre-
vious pelvic radiation therapy or previous or current malignant
disease of the pelvic organs; contraindications for anticholi-
nergics; nondrug treatment, including electro-stimulation ther-
apy (although bladder training or pelvic floor exercise
programs that had started more than 1 month prior to the start
of the study could be continued); use of other urinary incon-
tinence medications; known or suspected hypersensitivity to
tolterodine, other anticholinergics, mirabegron, lactose, or any
of the excipients; clinically significant cardiovascular (includ-
ing ECG abnormalities) or cerebrovascular disease; or any
other condition making the patient unsuitable for the study (as
deemed by the investigator).
Study design and procedures
This was a multinational, multicenter, randomized, double-
blind, double-dummy, parallel-group placebo- and active-
controlled phase II study. Patients were enrolled into a
single-blind, 2-week placebo run-in period followed by a
12-week double-blind treatment period in which patients
were randomized to receive one of the following: an
OCAS formulation of mirabegron QD at a dose of 25, 50,
100 or 200 mg, placebo or tolterodine ER 4 mg QD. There
were six study visits: visit 1 (screening); visit 2 (baseline)
after placebo run-in; and visits 3, 4, 5, and 6 after 1, 4, 8, and
12 weeks of treatment, respectively.
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At visit 1, eligible patients received a micturition diary,
used to evaluate mirabegron efficacy, which was to be
completed during the 3 days preceding all visits after
screening. For each micturition or incontinence episode,
patients rated the degree of associated urgency on the
five-point Patient’s Perception of Intensity of Urgency
Scale (0, no urgency; 1, mild urgency; 2, moderate urgen-
cy; 3, severe urgency; and 4, urge incontinence) [11]. At
visit 2, micturition diary scores were checked against
inclusion criteria to confirm study eligibility.
Overactive bladder symptoms and quality of life (QOL)
were assessed using the International Consultation on
Incontinence Questionnaire-Overactive Bladder (ICIQ-
OAB) [12, 13] and ICIQ-OAB QOL (ICIQ-OABqol) [14]
questionnaires. Patients’ assessment of treatment benefit
was also evaluated, starting at visit 2, with the question
“has the treatment been of any benefit to you?” (possible
responses: “no,” “yes, a little,” or “yes, very much”). These
were assessed at all five study visits after screening.
Observed and spontaneously reported adverse events
(AEs) were assessed at all visits, post-screening. Vital signs
(heart rate, systolic and diastolic blood pressures) were
measured by the investigator at visit 1 (screening) and by
the patient in triplicate, twice-daily (BID), during the 3-day
diary period preceding each visit in accordance with avail-
able guidelines [15]. 12-lead ECGs were performed at visits
1, 2, 3, 4 and 6. Blood and urine samples for safety assess-
ments (hematology, biochemistry, urinalysis and urine cul-
ture) were collected by a central laboratory at visits 1, 3, 4,
5, and 6, and PVRwas assessed by ultrasonography or bladder
scan at visits 1 and 6.
The study was conducted in accordance with the
Declaration of Helsinki (1996) and Good Clinical Practice
(GCP) guidelines. Institutional Review Board and local
Independent Ethics Committee approval for the protocol
and amendments was obtained and patients provided written
informed consent before any procedures.
Study endpoints
The primary efficacy endpoint was the change from
baseline to end-of-treatment in the mean number of mic-
turitions per 24 h. Secondary endpoints included changes
in mean volume voided per micturition; mean number of
urinary incontinence, urgency urinary incontinence, and
urgency episodes per 24 h; severity of urgency; number
of nocturia episodes; changes in ICIQ-OAB and ICIQ-
OABqol symptom scores, and in patients’ perception of
treatment benefit. Safety endpoints were incidence and
severity of AEs, and changes from baseline to end-of-
treatment in vital signs, laboratory tests, ECG parameters,
and PVR.
Statistical analysis
A primary goal was to ascertain if there was a statistically
significant improvement in the mean number of micturitions
per 24 h in at least one active treatment group. Assuming a
common standard deviation (SD) of 2.7 in the mean number
of micturitions per 24 h, the ability to detect with 80 % power
at an alpha level of 0.05 and a difference in means character-
ized by a variance of means of 0.126, it was necessary to
recruit 140 patients to each of the five treatment arms (four
mirabegron arms and a placebo arm). As tolterodine was
included as an active control and was not included in the
formal sample size calculation, a group of 70 patients in this
arm was expected to be sufficient to establish assay sensitivity
in evaluating the efficacy of mirabegron versus tolterodine.
The study plan was to have at least 770 evaluable patients.
The primary analysis assessed changes from baseline to
end-of-treatment in the mean number of micturitions per 24 h
using an analysis of covariance (ANCOVA) model with treat-
ment group (mirabegron dose) and country as fixed factors.
The baseline value of the mean number of micturitions per
24 h was included in the models as a covariate. The null
hypothesis, that the change in the mean number of micturi-
tions per 24 h from baseline to end-of-treatment was the same
for all mirabegron doses and for placebo, was evaluated using
a two-sided test with a 0.05 significance level. Pairwise com-
parisons between each mirabegron group and placebo were
performed; p values and 95 % confidence intervals (CIs) were
obtained. The tolterodine group was not part of this primary
analysis. The analysis described above was also performed for
secondary efficacy variables. The percentage of patients
showing a response in micturition frequency (defined as a
mean of less than eight micturitions per 24 h), incontinence
(patients who became dry), urgency, and nocturia episodes per
24 h (no episodes of either at a given visit) were compared
between treatment groups usingMantel–Haenszel procedures.
In a secondary analysis, pairwise comparisons between
tolterodine and placebo and between tolterodine and each
mirabegron group were performed using the ANCOVA
model described above.
The sum of scores for the ICIQ-OAB, ICIQ-OABqol, and
mean changes from visit 2 to the end-of-treatment were de-
rived for these variables and analyzed using the same
ANCOVA model as for the primary variable. Frequencies
and percentages for patients’ assessment of treatment benefit
at end-of-treatment were reported. A responder for treatment
benefit was defined by an improvement of at least one cate-
gory at a visit relative to baseline (i.e., the response changing
from “no” to “yes, a little”; from “no” to “yes, very much”; or
from “yes, a little” to “yes, very much”). Efficacy data were
analyzed using last observation carried forward (LOCF) meth-
odology. Safety variables were analyzed descriptively.
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Results
Study patients
A total of 1,108 patients were enrolled and 928 were ran-
domized (Fig. 1); 927 patients received at least one dose of
study medication (safety analysis set) and of these, 919
patients had primary efficacy data at baseline and at least
one on-treatment visit (full analysis set [FAS]). At least
90 % of patients in each group completed the study. At
week 12, data were obtained from a total of 854 subjects;
thus, 65 subjects (7 %) without a week 12 measurement
were analyzed at endpoint (LOCF). The study groups were
well balanced with respect to demographic characteristics, type
of OAB and prior drug therapy (Table 1). Approximately 30%
of patients had previously received nondrug therapy; this con-
sisted mostly of exercises, electrical stimulation, behavioral
training, and surgery. The mean duration of exposure to study
medication ranged from 80 to 84.4 days across groups.
Compliance was at least 98.5 % across treatment groups.
Primary efficacy endpoint
The reduction (improvement) from baseline to end-of-
treatment in the mean number of micturitions per 24 h
increased with mirabegron dose and the improvement rela-
tive to placebo was statistically significant (p≤0.05) for the
mirabegron 50-, 100-, and 200-mg groups (Table 2);
mirabegron 25, 50, 100, and 200 mg resulted in a mean
baseline to end-of-treatment reduction of 1.9, 2.1, 2.1, and
2.2 micturitions per 24 h, respectively, compared with 1.4
micturitions per 24 h with placebo. No statistically signifi-
cant differences in change in micturition frequency from
baseline to end-of-treatment were noted between tolterodine
and placebo or between tolterodine ER 4 mg and any
mirabegron group.
The percentage of patients classified as responders for
micturition frequency at the endpoint (mean of less than
eight micturitions per 24 h) were 19.3 % for placebo,
28.7 % for mirabegron 25 mg, and 30.1 % for the mirabe-
gron 200-mg group (p≤0.05 for all mirabegron dose groups
versus placebo). For the tolterodine ER 4-mg group, 18.8 %
of patients were classified as responders; the difference
relative to placebo was not statistically significant (Table 3).
Secondary efficacy endpoints
Urinary symptoms
Mean baseline to end-of-treatment improvements relative to
placebo were statistically significant for mirabegron for
mean volume voided per micturition (at doses of 50, 100,
and 200 mg); incontinence episodes (at doses of 25 and
50 mg); urgency incontinence episodes (at doses of 25, 50,
100 and 200 mg); urgency episodes (at doses of 25, 100, and
200 mg); level of urgency (at doses of 100 and 200 mg);
Fig. 1 Disposition of subjects.
MIRA mirabegron, TOL
tolterodine, AE adverse event,
CW consent withdrawn, PV
protocol violation, LOE lack of
efficacy, LTFU lost to follow-
up. MIRA and TOL were
administered once daily.
Asterisks: In the mirabegron
100-mg group, 169 patients
were randomized and 168
received treatment. Dagger:
Other reasons for
discontinuation included
laboratory value out of range
and medical advice to stop
study drug (25-mg group);
noncompliance and patient
decision (50-mg group); and a
patient stopped taking the study
drug during hospitalization for
arthroscopy of the knee (200-
mg group)
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and nocturia episodes (at a dose of 50 mg) (p<0.05 for all
comparisons; Table 2).
A statistically significant difference (p<0.01) between
tolterodine and placebo was noted for mean volume
voided per micturition, but not for other secondary end-
points. Statistically significant differences (p≤0.05) favor-
ing the mirabegron 200-mg group relative to tolterodine
were noted for grade at ≥3 urgency episodes (and level of
urgency).
The percentage of patients classified as responders for
incontinence episodes at the end of treatment (patients
who became dry) was 36.8 % for placebo; 41.7–55.9 %
across the four mirabegron groups (p≤0.05 for all mir-
abegron groups versus placebo); and 35.8 % for tolter-
odine. At the end of treatment, more patients in the
mirabegron than in the placebo group were responders
with respect to urgency (grade ≥3) and nocturia episodes
(no episodes of either at the end of treatment), although
differences between groups were not statistically signifi-
cant. The responder levels for urgency and nocturia epi-
sodes for the tolterodine ER 4-mg group were similar to
those seen for placebo (Table 3).
Quality of life
The positive effect of mirabegron on QOL scores (a reduc-
tion in ICIQ-OAB score indicated improvement) increased
with mirabegron dose (Table 2); moreover, the change from
baseline to the end of treatment for all mirabegron groups
was statistically significant versus placebo (p≤0.05).
Improvements from baseline to the end of treatment were
also observed with the ICIQ-OABqol questionnaire, al-
though only the comparison between the mirabegron
200-mg group and placebo was statistically significant
(−22.19 versus −16.11, p≤0.05; Table 2).
No statistically significant differences between tolterodine
ER 4 mg and placebo were noted for the QOL scores obtained
on both the ICIQ-OAB and ICIQ-OABqol. A statistically
significant treatment effect favoring mirabegron 200 mg com-
pared with tolterodine ER 4 mg (−3.05 versus −2.21, p<0.05)
was seen on the ICIQ-OAB.
The percentage of patients classified as “responders” in
patient perception of treatment benefit (improvement of ≥1
category from baseline) at the end of treatment was 59.0 %,
65.0 %. 65.8 % and 70.8 % for the mirabegron 25-mg,
Table 1 Demographic and baseline characteristics (full analysis set)a
Characteristic Placebo Mirabegron OCASc Tolterodine ER
(n=166) 25 mg (n=167) 50 mg (n=167) 100 mg (n=168) 200 mg (n=166) 4 mgc (n=85)
Age (years)±SD 57.1±12.9 57.2±12.1 56.9±12.5 57.1±12.5 58.0±13.7 56.6±12.8
Sex, n (%)
Male 15 (9.0) 20 (12.0) 18 (10.8) 17 (10.1) 12 (7.2) 16 (18.8)
Female 151 (91.0) 147 (88.0) 149 (89.2) 151 (89.9) 154 (92.8) 69 (81.2)
Race, n (%)
Asian 0 1 (0.6) 0 1 (0.6) 0 2 (2.4)
Black 0 2 (1.2) 0 0 0 0
White 166 (100) 162 (97.0) 162 (97.0) 167 (99.4) 164 (98.8) 81 (95.3)
Other 0 1 (0.6) 3 (1.8) 0 0 1 (1.2)
Missing 0 1 (0.6) 2 (1.2) 0 2 (1.2) 1 (1.2)
Type of OAB, n (%)
Urge incontinence only 74 (44.6) 79 (47.3) 67 (40.1) 67 (39.9) 63 (38.0) 38 (44.7)
Mixed incontinenceb 52 (31.3) 41 (24.6) 47 (28.1) 54 (32.1) 63 (38.0) 24 (28.2)
Without incontinence 40 (24.1) 47 (28.1) 53 (31.7) 47 (28.0) 40 (24.1) 23 (27.1)
Prior drug therapy, n (%)
Yes, at least one effective 41 (24.7) 40 (24.0) 39 (23.4) 42 (25.0) 34 (20.5) 19 (22.4)
Yes, none effective 30 (18.1) 42 (25.1) 38 (22.8) 39 (23.2) 38 (22.9) 16 (18.8)
No 95 (57.2) 85 (50.9) 90 (53.9) 87 (51.8) 94 (56.6) 50 (58.8)
Non-drug therapy, n (%) 51 (30.7) 57 (34.1) 49 (29.3) 44 (26.2) 40 (24.1) 22 (25.9)
OCAS oral controlled absorption system, ER extended release, OAB overactive bladder, SD standard deviation
a Full analysis set means all patients with primary efficacy data at baseline and at least one on-treatment visit
b Urge was the predominant factor
cMirabegron and tolterodine were administered once daily (QD)
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Table 2 Adjusted changes from baseline to endpoint and estimated differences versus placebo for efficacy variables by treatment group (full
analysis set)
Placebo Mirabegron OCASb Tolterodine ERc
25 mg 50 mg 100 mg 200 mg 4 mg
Micturitions/24 h n=166 n=167 n=167 n=168 n=166 n=85
Adjusted mean CFB −1.44 −1.88 −2.08 −2.12 −2.24 −1.99
Estimated difference from placebo −0.45 −0.64* −0.68* −0.80** −0.52
95 % CIs −0.99, 0.10 −1.19 , −0.10 −1.22, −0.13 −1.34, −0.25 −1.18, 0.15
Mean volume voided/micturition (ml) n=165 n=167 n=167 n=168 n=166 n=85
Adjusted mean CFB 7.29 15.32 27.34 25.56 33.34 23.86
Estimated difference from placebo 8.03 20.05*** 18.28*** 26.06*** 16.81*
95 % CIs −1.54, 17.60 10.48, 29.63 8.66, 27.89 16.49, 35.62 5.09, 28.5
Incontinence episodes/24 h n=106 n=99 n=108 n=111 n=110 n=53
Adjusted mean CFB −0.53 −1.36 −1.15 −1.06 −1.10 −0.81
Estimated difference from placebo −0.84** −0.62* −0.53 −0.58 −0.28
95 % CIs −1.45, −0.23 −1.22, −0.02 −1.12, 0.06 −1.16, 0.01 −1.01, 0.45
Nocturia episodes/24 h n=144 n=145 n=142 n=141 n=147 n=72
Adjusted mean CFB −0.38 −0.52 −0.60 −0.42 −0.59 −0.59
Estimated difference from placebo −0.15 −0.22* −0.04 −0.21 −0.21
95 % CIs −0.36, 0.07 −0.44, −0.01 −0.26, 0.17 −0.43, 0.00 −0.47, 0.05
Urgency incontinence episodesa/24 h n=106 n=93 n=106 n=107 n=108 n=52
Adjusted mean CFB −0.44 −1.31 −1.13 −1.18 −1.24 −0.76
Estimated difference from placebo −0.86** −0.69** −0.74** −0.80** −0.31
95 % CIs −1.38, −0.35 −1.18, −0.19 −1.23, −0.25 −1.29, −0.31 −0.92, 0.30
Urgency episodes/24 h (severity ≥3) n=165 n=167 n=166 n=168 n=165 n=85
Adjusted mean CFB −1.07 −1.77 −1.67 −2.28 −2.48 −1.46
Estimated difference from placebo −0.70* −0.60 −1.21*** −1.42*** −0.37
95 % CIs −1.38, −0.01 −1.29, 0.08 −1.90, −0.52 −2.10, −0.73 −1.21, 0.47
Level of urgency/24 h n=166 n=166 n=166 n=168 n=166 n=85
Adjusted mean CFB −0.10 −0.21 −0.18 −0.29 −0.38 −0.14
Estimated difference from placebo −0.12 −0.08 −0.19** −0.28*** −0.04
95 % CIs −0.25, 0.02 −0.22, 0.05 −0.33, −0.06 −0.41, −0.15 −0.21, 0.12
ICIQ-OAB n=166 n=167 n=166 n=168 n=166 n=85
Adjusted mean CFB −1.82 −2.40 −2.51 −2.72 −3.02 −2.21
Estimated difference from placebo −0.58* −0.69* −0.90** −1.20*** −0.37
95 % CIs −1.13, −0.02 −1.24, −0.13 −1.45, −0.34 −1.76, −0.65 −1.05, 0.31
ICIQ-OABqol n=162 n=163 n=165 n=163 n=162 n=84
Adjusted mean CFB −16.11 −17.09 −20.36 −20.57 −22.19 −17.42
Estimated difference from placebo −0.98 −4.25 −4.46 −6.08* −1.32
95 % CIs −5.88, 3.92 −9.13, 0.62 −9.37, 0.46 −11.0, −1.19 −7.32, 4.69
OCAS oral controlled absorption system, CFB change from baseline, CI confidence interval, ICIQ International Consultation on Incontinence
Questionnaire, OAB overactive bladder, qol quality of life
*p≤0.05, **p≤0.01, ***p≤0.001
a Urgency incontinence (incontinence with urgency) is a subset of incontinence (with or without urgency)
bMirabegron was administered once daily (QD)
c The statistics for values given in the placebo and mirabegron columns come from the primary analysis, in which treatment group was included as a
fixed factor in the ANCOVA model; pairwise comparisons between each mirabegron group and placebo were performed; the tolterodine group was
excluded. The statistics for values in the tolterodine column come from the secondary analysis in which tolterodine was also included as a fixed
factor; in this analysis, pairwise comparisons between tolterodine and placebo and between tolterodine and each mirabegron group were performed
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50-mg, 100-mg, and 200-mg groups, respectively, compared
with 51% for placebo. Approximately 55% of the tolterodine
ER 4-mg patients were classified as responders on this
measure.
Safety
The incidence of treatment-related AEs was comparable for
the mirabegron and placebo groups (Table 4). Dry mouth
was more common with tolterodine ER 4 mg (3.5 %) than
with mirabegron (1.8 % to 3.0 % depending on dose).
Discontinuation owing to AEs was low at 3.0 % (placebo),
2.4–5.3 % (mirabegron groups), and 1.2 % (tolterodine).
Serious adverse events were reported in <2 % of patients
across treatment groups; two events, one of pneumonia and
one of hypothyroidism, were considered to be possibly
related to mirabegron.
A statistically significant increase in pulse rate from
baseline was seen with mirabegron 100 and 200 mg ver-
sus placebo. In addition, pulse rate was seen to increase in
a dose-related manner. The adjusted mean change in
morning pulse rate from baseline was 0.51 bpm for pla-
cebo, 2.15 bpm for mirabegron 100 mg (p≤0.05), and
4.66 bpm for mirabegron 200 mg (p≤0.001). Similarly,
the adjusted mean change in afternoon pulse rate from
baseline was –0.04 bpm for placebo, 2.71 bpm for mir-
abegron 100 mg (p≤0.001), and 4.63 bpm for mirabegron
200 mg (p≤0.001). However, this was not associated with
a clinically significant increase in cardiovascular AEs (for
example, atrial fibrillation or palpitations), the incidence
of which was comparable to that seen with tolterodine.
Morning and afternoon pulse rate increases from baseline for
the mirabegron 25-mg (0.34 and 0.44 bpm, respectively) and
50-mg (1.64 and 1.12 bpm, respectively) groups were not
statistically significant compared with placebo. By compari-
son, the adjusted mean changes from baseline in the morning
and afternoon pulse rates seen with tolterodine were 1.50 and
2.50, respectively. No drug effect on systolic or diastolic blood
pressure was observed; the net changes in morning and after-
noon blood pressure from baseline in all mirabegron groups
were <2 mm Hg and comparable to placebo. No differences
between treatment groups were observed with respect to ECG
parameters, including QTcF. Mean changes in PVR were
small, at –4.6 ml for placebo; –4.7, –4.3, 0.6, and –3.0 mL
formirabegron 25, 50, 100, and 200mg, respectively; and –1.3
for tolterodine ER 4 mg. There were no clinically relevant
changes in laboratory parameters.
Discussion
In this study, mirabegron OCAS was effective and well
tolerated with clear dose-dependent efficacy above
50 mg. The difference in response versus placebo was
evident after 1 week of treatment and a maximum effect
was achieved and sustained from 8 to 12 weeks, as seen
in previous studies evaluating antimuscarinic therapy for
OAB [16]. Approximately half of the incontinent patients
in each mirabegron treatment group (from 41.7 % of the
mirabegron 50-mg group to 55.9 % of the mirabegron
100-mg group) were dry at the end of treatment. Thus,
mirabegron exhibited considerable clinical benefit as
Table 3 Number (%) of respondersa for selected efficacy variables at the study endpoint (full analysis set)
Placebo Mirabegron OCASb Tolterodine ERb
25 mg 50 mg 100 mg 200 mg 4 mg
Patients, n (%)c
Micturitions/24 h* n=166 n=167 n=167 n=168 n=166 n=85
32 (19.3) 48 (28.7) 46 (27.5) 55 (32.7) 50 (30.1) 16 (18.8)
Incontinence episodes/24 h* n=106 n=99 n=108 n=111 n=110 n=53
39 (36.8) 42 (42.4) 45 (41.7) 62 (55.9) 53 (48.2) 19 (35.8)
Urgency episodes (grade ≥3)/24 h n=165 n=167 n=166 n=168 n=165 n=85
25 (15.2) 27 (16.2) 24 (14.5) 33 (19.6) 36 (21.8) 13 (15.3)
Nocturia episodes/24 h n=144 n=145 n=142 n=141 n=147 n=72
21 (14.6) 34 (23.4) 34 (23.9) 20 (14.2) 34 (23.1) 13 (18.1)
OCAS oral controlled absorption system, ER extended release
*p≤0.05 based on a Mantel–Haenszel test to compare all treatment groups, except tolterodine
a Responder definitions: micturitions, <8 micturitions/24 h; incontinence episodes, no episodes (patient became dry); urgency and nocturia
episodes, no episodes of either
bMirabegron and tolterodine were administered once daily (QD)
c Percentages are based on the number of patients with available data at the endpoint
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demonstrated by consistently improved symptoms of
OAB and associated QOL measures.
The mirabegron doses of 25, 50, 100, and 200 mg QD
used in this study were based on the results of a proof-of-
concept study in which total daily doses of 200 and 300 mg
(100 and 150 mg BID, respectively) were investigated.
Notably, a QD OCAS formulation was utilized in this study.
In the proof-of-concept study, no difference in efficacy was
seen between the 100-mg and 150-mg BID doses, leading to
the conclusion that a total daily dose of 200 mg provides
maximum therapeutic efficacy. Hence, this was the highest
dose investigated in the current study.
Tolterodine is a licensed antimuscarinic antagonist for
OAB that was used as an active control for mirabegron in
this study in order to give context to the efficacy and
safety results seen with mirabegron. Hence, it is notable
that the magnitude of improvements in efficacy outcomes
in the mirabegron groups were within the same range as
those of the tolterodine ER 4-mg group, further suggesting
that mirabegron is a potentially effective treatment for the
management of patients with OAB. However, one limita-
tion of this study is that it was not powered to detect
differences between mirabegron and tolterodine for which
head-to-head comparison studies are required. In addition,
the short duration of this study could also be perceived as
a limitation, as it allows no insight into the long-term
effects of mirabegron, notably whether its favorable effi-
cacy and tolerability profile is maintained over a pro-
longed period and whether it leads to improved
compliance. However, this was a phase II study, designed
as a dose-finding study, and its design and conduct are
usual and adequate for that purpose. It is worth noting too
that between 24.6 % and 38.0 % of the patients across
treatment groups had urge-predominant mixed inconti-
nence at baseline.
Mirabegron was found to be well tolerated with a low
incidence of AEs, between that seen with placebo and tolter-
odine. Dry mouth is the most common, and most bothersome
side effect of antimuscarinic treatment [16–19]. Thus, the low
incidence of dry mouth seen with mirabegron and the
observation that its incidence was lower with mirabegron
than with tolterodine may be an important benefit of
mirabegron treatment. The small mean increase in pulse
rate from baseline observed with mirabegron was less
pronounced than that reported in other studies [20, 21]
and was not associated with a clinically significant in-
crease in cardiovascular AEs. There was no evidence of
a dose–response relationship for these events and none of
Table 4 Treatment-related AEs reported during treatment (safety populations)a
System organ class preferred term Placebo
(n=169)
Mirabegron Mirabegron Mirabegron Mirabegron Tolterodine
OCAS OCAS OCAS OCAS ER
25 mgb 50 mg 100 mg 200 mg 4 mg
(n=169) (n=169) (n=168) (n=167) (n=85)
Patients, n (%)
Overall 26 (15.4) 34 (20.1) 38 (22.5) 36 (21.4) 37 (22.2) 13 (15.3)
Cardiac disorders 1 (0.6) 4 (2.4) 7 (4.1) 2 (1.2) 5 (3.0) 1 (1.2)
Eye disorders 3 (1.8) 3 (1.8) 2 (1.2) 1 (0.6) 6 (3.6) 0 (0.0)
Gastrointestinal disorders 9 (5.3) 14 (8.3) 14 (8.3) 16 (9.5) 12 (7.2) 7 (8.2)
Constipation 2 (1.2) 2 (1.2) 4 (2.4) 3 (1.8) 3 (1.8) 1 (1.2)
Dry mouth 3 (1.8) 5 (3.0) 3 (1.8) 5 (3.0) 3 (1.8) 3 (3.5)
Dyspepsia 1 (0.6) 1 (0.6) 1 (0.6) 0 (0.0) 4 (2.4) 0 (0.0)
Nausea 2 (1.2) 2 (1.2) 2 (1.2) 7 (4.2) 1 (0.6) 1 (1.2)
General disorders and administration site conditions 2 (1.2) 3 (1.8) 6 (3.6) 3 (1.8) 1 (0.6) 1 (1.2)
Investigations 9 (5.3) 10 (5.9) 4 (2.4) 6 (3.6) 7 (4.2) 1 (1.2)
Gamma-glutamyl transferase increased 2 (1.2) 4 (2.4) 0 (0.0) 2 (1.2) 2 (1.2) 0 (0.0)
Nervous system disorders 6 (3.6) 7 (4.1) 10 (5.9) 7 (4.2) 6 (3.6) 1 (1.2)
Dizziness 1 (0.6) 0 (0.0) 6 (3.6) 2 (1.2) 0 (0.0) 0 (0.0)
Headache 4 (2.4) 6 (3.6) 5 (3.0) 4 (2.4) 3 (1.8) 1 (1.2)
Psychiatric disorders 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.6) 2 (2.4)
Vascular disorders 4 (2.4) 4 (2.4) 4 (2.4) 6 (3.6) 2 (1.2) 0 (0.0)
OCAS oral controlled absorption system, ER extended release
a The AEs listed were reported in ≥2 % of the patients in either treatment group
bMirabegron and tolterodine were administered once daily (QD)
1454 Int Urogynecol J (2013) 24:1447–1458
the patients discontinued the study because of symptoms
associated with increased heart rate.
The favorable efficacy and tolerability profile of mirabe-
gron, the first in this new class of compounds to be ap-
proved for the treatment of the symptoms of OAB, in once-
daily doses ranging from 25 to 200 mg OCAS, has led to its
successful advancement into a phase III clinical develop-
ment program at doses of 25, 50, and 100 mg.
Conclusions
The satisfactory balance between efficacy and tolerability
observed in this study of mirabegron in OAB patients
may result in improved compliance compared with that
seen with currently available antimuscarinics, whose use
is hampered by bothersome side effects and insufficient
efficacy.
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